Literature DB >> 7949215

4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro.

J N Sarkaria1, E M Miller, C J Parker, V C Jordan, R T Mulcahy.   

Abstract

The effect of 4-hydroxytamoxifen (4OH-TAM), the potent anti-estrogenic metabolite of tamoxifen, on the radiosensitivity of MCF-7 cells irradiated in vitro was determined. Radiation dose response curves were generated for MCF-7 cells maintained and irradiated in phenol red-free medium containing 10(-10) M estradiol (E2) with or without 10(-7) M 4OH-TAM. Immediately after irradiation cells were transferred to medium containing 10(-10) ME2 supplemented with bovine serum to stimulate colony formation. Estradiol-stimulated cell proliferation was inhibited by 10(-7) M 4OH-TAM, but radiation sensitivity was not significantly altered (p > 0.3). Continued incubation in the absence of E2 for an additional 24 hours after irradiation likewise failed to alter the radiosensitivity of 4OH-TAM-treated MCF-7 cells. These studies indicate that growth-inhibitory concentrations of the anti-estrogen 4OH-TAM do not modify the in vitro radiation sensitivity of this line of human breast carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949215     DOI: 10.1007/bf00666060

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  25 in total

1.  Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2'-deoxyuridine labelling: a flow cytometric study of 75 tumours.

Authors:  D A Rew; I D Campbell; I Taylor; G D Wilson
Journal:  Br J Surg       Date:  1992-04       Impact factor: 6.939

2.  Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen.

Authors:  D E Wazer; O F Tercilla; P S Lin; R Schmidt-Ullrich
Journal:  Br J Radiol       Date:  1989-12       Impact factor: 3.039

3.  Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer.

Authors:  L E Rutqvist; B Cedermark; U Glas; H Johansson; S Rotstein; L Skoog; A Somell; T Theve; N Wilking; J Askergren
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860

Review 4.  Radiation-induced potentially lethal damage: DNA lesions susceptible to fixation.

Authors:  G Iliakis
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1988-04

5.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.

Authors:  V C Jordan; M M Collins; L Rowsby; G Prestwich
Journal:  J Endocrinol       Date:  1977-11       Impact factor: 4.286

6.  Global comparison of radiation and chemotherapy dose-response curves with a test for interaction.

Authors:  M J Lindstrom; K A Kunugi; T J Kinsella
Journal:  Radiat Res       Date:  1993-08       Impact factor: 2.841

7.  Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.

Authors:  M H Jeng; C J Parker; V C Jordan
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

Review 8.  Keynote address: integration of cytostatic agents and radiation therapy: a different approach to "proliferating" human tumors.

Authors:  T J Kinsella; M N Gould; R T Mulcahy; M A Ritter; J F Fowler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-02       Impact factor: 7.038

9.  Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.

Authors: 
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

10.  Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7.

Authors:  A E Lykkesfeldt; J K Larsen; I J Christensen; P Briand
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

View more
  6 in total

1.  Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.

Authors:  Guler Yavas; Cagdas Yavas; Hilal Acar; Hatice Toy; Deniz Yuce; Ozlem Ata
Journal:  Support Care Cancer       Date:  2012-09-01       Impact factor: 3.603

2.  Letrozole sensitizes breast cancer cells to ionizing radiation.

Authors:  David Azria; Christel Larbouret; Severine Cunat; Mahmut Ozsahin; Sophie Gourgou; Pierre Martineau; Dean B Evans; Gilles Romieu; Pascal Pujol; Andre Pèlegrin
Journal:  Breast Cancer Res       Date:  2004-12-07       Impact factor: 6.466

3.  Estrogen enhanced cell-cell signalling in breast cancer cells exposed to targeted irradiation.

Authors:  Chunlin Shao; Melvyn Folkard; Kathryn D Held; Kevin M Prise
Journal:  BMC Cancer       Date:  2008-06-30       Impact factor: 4.430

Review 4.  Estrogen Receptor Signaling in Radiotherapy: From Molecular Mechanisms to Clinical Studies.

Authors:  Chao Rong; Étienne Fasolt Richard Corvin Meinert; Jochen Hess
Journal:  Int J Mol Sci       Date:  2018-03-02       Impact factor: 5.923

5.  Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients.

Authors:  D Azria; S Gourgou; W J Sozzi; A Zouhair; R O Mirimanoff; A Kramar; C Lemanski; J B Dubois; G Romieu; A Pelegrin; M Ozsahin
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

6.  Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms.

Authors:  Qi Fang; Shuang Yao; Guanghua Luo; Xiaoying Zhang
Journal:  Oncotarget       Date:  2017-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.